$RXST
Rxsight Inc Stock $rxst

$rxst Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023006237 Filed on March 06, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$17.49M	$16.09M	$49.01M
YoY Change	95.58%	90.93%	116.9%
Cost Of Revenue	$7.123M	$8.666M	$27.68M
YoY Change	37.48%	55.95%	53.11%
Gross Profit	$10.37M	$7.422M	$21.33M
YoY Change	175.62%	158.7%	372.17%
Gross Profit Margin	59.27%	46.13%	43.52%
Selling, General & Admin	$16.26M	$15.80M	$58.67M
YoY Change	19.35%	35.23%	78.83%
% of Gross Profit	156.81%	212.92%	275.06%
Research & Development	$7.208M	$6.599M	$25.98M
YoY Change	7.28%	12.98%	6.05%
% of Gross Profit	69.54%	88.91%	121.82%
Depreciation & Amortization	$955.0K	$961.0K	$3.884M
YoY Change	-6.0%	-5.69%	-2.29%
% of Gross Profit	9.21%	12.95%	18.21%
Operating Expenses	$23.46M	$22.41M	$84.65M
YoY Change	15.36%	27.83%	47.71%
Operating Profit	-$13.10M	-$14.99M	-$63.32M
YoY Change	-21.0%	2.23%	19.95%
Interest Expense	$1.507M	-$615.0K	$4.946M
YoY Change	42.17%	-42.47%	34.33%
% of Operating Profit
Other Income/Expense, Net		$0.00	$0.00
YoY Change			-100.0%
Pretax Income	-$13.21M	-$15.61M	-$66.75M
YoY Change	-24.9%	-0.81%	37.11%
Income Tax	$0.00	$5.000K	$9.000K
% Of Pretax Income
Net Earnings	-$13.21M	-$15.61M	-$66.76M
YoY Change	-24.91%	-0.79%	37.11%
Net Earnings / Revenue	-75.54%	-97.03%	-136.22%
Basic Earnings Per Share	-$0.42		-$2.41
Diluted Earnings Per Share	-$0.42	-$0.51	-$2.41
COMMON SHARES
Basic Shares Outstanding	33.78M	27.72M	27.66M
Diluted Shares Outstanding	31.64M		27.66M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$153.9M	$105.8M	$105.8M
YoY Change	7.02%	-33.6%	-33.6%
Cash & Equivalents	$11.01M	$11.83M	$11.83M
Short-Term Investments	$142.9M	$93.97M	$93.97M
Other Short-Term Assets	$2.992M	$2.962M	$2.962M
YoY Change	-6.03%	-27.21%	-27.21%
Inventory	$18.07M	$14.84M	$14.84M
Prepaid Expenses
Receivables	$12.67M	$10.96M	$10.96M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$187.7M	$134.6M	$134.6M
YoY Change	16.46%	-23.68%	-23.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.804M	$10.14M	$14.08M
YoY Change	-10.18%	-9.62%	-9.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$746.0K	$767.0K	$1.528M
YoY Change	465.15%	572.81%	65.19%
Total Long-Term Assets	$14.87M	$15.61M	$15.61M
YoY Change	-6.59%	-4.97%	-4.97%
TOTAL ASSETS
Total Short-Term Assets	$187.7M	$134.6M	$134.6M
Total Long-Term Assets	$14.87M	$15.61M	$15.61M
Total Assets	$202.5M	$150.2M	$150.2M
YoY Change	14.38%	-22.08%	-22.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.717M	$2.595M	$2.595M
YoY Change	43.68%	53.64%	53.64%
Accrued Expenses	$11.05M	$12.67M	$10.81M
YoY Change	38.11%	61.24%	25.48%
Deferred Revenue		$1.348M
YoY Change		118.12%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$114.0K	$152.0K	$152.0K
YoY Change	52.0%	660.0%	660.0%
Total Short-Term Liabilities	$14.88M	$17.24M	$17.24M
YoY Change	39.56%	55.61%	55.61%
LONG-TERM LIABILITIES
Long-Term Debt	$40.31M	$40.21M	$40.21M
YoY Change	0.84%	1.09%	1.09%
Other Long-Term Liabilities	$2.338M	$2.813M	$2.813M
YoY Change	-28.41%	-22.4%	-22.4%
Total Long-Term Liabilities	$42.65M	$43.03M	$43.03M
YoY Change	-1.37%	-0.87%	-0.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.88M	$17.24M	$17.24M
Total Long-Term Liabilities	$42.65M	$43.03M	$43.03M
Total Liabilities	$57.52M	$60.26M	$60.26M
YoY Change	6.72%	10.62%	10.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$559.2M	-$546.0M
YoY Change	12.55%	13.93%
Common Stock	$34.00K	$28.00K
YoY Change	25.93%	3.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$145.0M	$89.90M	$89.90M
YoY Change
Total Liabilities & Shareholders Equity	$202.5M	$150.2M	$150.2M
YoY Change	14.38%	-22.08%	-22.08%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$13.21M	-$15.61M	-$66.76M
YoY Change	-24.91%	-0.79%	37.11%
Depreciation, Depletion And Amortization	$955.0K	$961.0K	$3.884M
YoY Change	-6.0%	-5.69%	-2.29%
Cash From Operating Activities	-$17.76M	-$13.85M	-$58.85M
YoY Change	18.55%	58.84%	31.63%
INVESTING ACTIVITIES
Capital Expenditures	$747.0K	$362.0K	$2.393M
YoY Change	101.89%	-199.18%	23.35%
Acquisitions
YoY Change
Other Investing Activities	-$47.62M	$10.77M	$42.34M
YoY Change	-412.68%	-130.78%	-152.95%
Cash From Investing Activities	-$48.37M	$10.41M	$39.95M
YoY Change	-425.49%	-129.44%	-148.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	65.31M	6.307M	6.332M
YoY Change	-66737.76%	1461.14%	-95.39%
NET CHANGE
Cash From Operating Activities	-17.76M	-13.85M	-58.85M
Cash From Investing Activities	-48.37M	10.41M	39.95M
Cash From Financing Activities	65.31M	6.307M	6.332M
Net Change In Cash	-822.0K	2.858M	-12.58M
YoY Change	258.95%	-106.55%	-217.36%
FREE CASH FLOW
Cash From Operating Activities	-$17.76M	-$13.85M	-$58.85M
Capital Expenditures	$747.0K	$362.0K	$2.393M
Free Cash Flow	-$18.51M	-$14.22M	-$61.24M
YoY Change	20.55%	70.11%	31.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20221231#LeaseLiabilitiesNoncurrent
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001111485
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20221231#LeaseLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20221231#LeaseLiabilitiesCurrent
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20221231#LeaseLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20221231#LeaseLiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20221231#LeaseLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20221231#LeaseLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20221231#LeaseLiabilitiesNoncurrent
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40690
CY2022	dei	Entity Registrant Name EntityRegistrantName	RxSight, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3268801
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Columbia
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Aliso Viejo
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92656
CY2022	dei	City Area Code CityAreaCode	949
CY2022	dei	Local Phone Number LocalPhoneNumber	521-7830
CY2022	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	RXST
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	310000000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33775718
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28268389
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young, LLP
CY2022	dei	Auditor Location AuditorLocation	Irvine, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11834000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24361000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	93968000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	134971000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10956000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4862000
CY2022Q4	us-gaap	Inventory Net InventoryNet	14835000
CY2021Q4	us-gaap	Inventory Net InventoryNet	8032000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2962000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4069000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	134555000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	176295000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10138000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11217000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3943000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4284000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	761000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	811000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	767000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	114000
CY2022Q4	us-gaap	Assets Assets	150164000
CY2021Q4	us-gaap	Assets Assets	192721000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2595000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1689000
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12672000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7859000
CY2022Q4	rxst	Lease Liabilities Current LeaseLiabilitiesCurrent	1970000
CY2021Q4	rxst	Lease Liabilities Current LeaseLiabilitiesCurrent	1529000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17237000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11077000
CY2022Q4	rxst	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	2856000
CY2021Q4	rxst	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	3642000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	40169000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	39760000
CY2022Q4	us-gaap	Liabilities Liabilities	60262000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28268389
CY2021Q4	us-gaap	Liabilities Liabilities	54479000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27366746
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27366746
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	28000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	27000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	636001000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	617511000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-95000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-546032000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-479276000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	89902000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	138242000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	150164000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	192721000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49005000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22593000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	27677000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18076000
CY2022	us-gaap	Gross Profit GrossProfit	21328000
CY2021	us-gaap	Gross Profit GrossProfit	4517000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	58665000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32805000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25981000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24499000
CY2022	us-gaap	Operating Expenses OperatingExpenses	84646000
CY2021	us-gaap	Operating Expenses OperatingExpenses	57304000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-63318000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-52787000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2717000
CY2022	rxst	Expiration Of Warrant ExpirationOfWarrant	0
CY2021	rxst	Expiration Of Warrant ExpirationOfWarrant	-5018000
CY2022	us-gaap	Interest Expense InterestExpense	4946000
CY2021	us-gaap	Interest Expense InterestExpense	3682000
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	1517000
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	54000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-66747000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48680000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-66756000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-48688000
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-66000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-7000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-10000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-75000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-17000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66831000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48705000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.41
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.41
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.57
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.57
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27661982
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27661982
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13625044
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13625044
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-430591000
CY2021	rxst	Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount	347000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7575000
CY2021	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	136000
CY2021	rxst	Redeemable Common Stock Reclassified Shares RedeemableCommonStockReclassifiedShares	4093995
CY2021	rxst	Common Stock After Reclassification Of Redeemable Common Stock Shares CommonStockAfterReclassificationOfRedeemableCommonStockShares	4093995
CY2021	rxst	Common Stock Issued During Period Value Conversion Of Redeemable Common Stock CommonStockIssuedDuringPeriodValueConversionOfRedeemableCommonStock	86885000
CY2021	rxst	Common Stock Options Issued During Period Value Conversion Of Redeemable Common Stock Options CommonStockOptionsIssuedDuringPeriodValueConversionOfRedeemableCommonStockOptions	47370000
CY2021	rxst	Change In Notes Receivable For Redeemable Common Stock Issued ChangeInNotesReceivableForRedeemableCommonStockIssued	452000
CY2021	rxst	Exercise Of Preferred Stock Warrants Net Of Shares Withheld For Exercise Price ExerciseOfPreferredStockWarrantsNetOfSharesWithheldForExercisePrice	-2011000
CY2021	rxst	Amount Of Settlement Of Fractional Shares AmountOfSettlementOfFractionalShares	11000
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	357202000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12400000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	119582000
CY2021Q4	rxst	Other Comprehensive Loss OtherComprehensiveLoss	-17000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-48688000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	138242000
CY2022	rxst	Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount	841000
CY2022	rxst	Shares Redeemed For Employee Tax With Holdings Amount SharesRedeemedForEmployeeTaxWithHoldingsAmount	-643000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11397000
CY2022	rxst	Shares Issued For The Employee Stock Purchase Plan Amount SharesIssuedForTheEmployeeStockPurchasePlanAmount	937000
CY2022	rxst	Issuance Of Common Stock In At The Market Offerings Net Of Issuance Costs Amount IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount	5959000
CY2022Q4	rxst	Other Comprehensive Loss OtherComprehensiveLoss	-75000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-66756000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	89902000
CY2022	us-gaap	Profit Loss ProfitLoss	-66756000
CY2021	us-gaap	Profit Loss ProfitLoss	-48688000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3884000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3975000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	138000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2717000
CY2022	rxst	Gain Loss On Expiration Of Warrant GainLossOnExpirationOfWarrant	0
CY2021	rxst	Gain Loss On Expiration Of Warrant GainLossOnExpirationOfWarrant	5018000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	13000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	493000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	552000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1405000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	30000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11397000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	7575000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	752000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2367000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6094000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1996000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7555000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2111000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-789000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2809000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	635000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	555000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4813000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3683000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-58850000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44708000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2393000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1940000
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	255000000
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	80000000
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	212657000
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	159967000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39950000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81907000
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	15000000
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	145000
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	132000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	790000
CY2022	rxst	Proceeds From Exercise Of Stock Options And Issuance Of Common Stock Under The Employee Stock Purchase Plan ProceedsFromExerciseOfStockOptionsAndIssuanceOfCommonStockUnderTheEmployeeStockPurchasePlan	1778000
CY2022	rxst	Payments For Employee Taxes Related To Stock Compensation PaymentsForEmployeeTaxesRelatedToStockCompensation	-643000
CY2021	rxst	Payments For Employee Taxes Related To Stock Compensation PaymentsForEmployeeTaxesRelatedToStockCompensation	0
CY2022	rxst	Proceeds From Initial Public Offering Net Of Underwriting Discounts And Commissions And Offering Costs ProceedsFromInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissionsAndOfferingCosts	0
CY2021	rxst	Proceeds From Initial Public Offering Net Of Underwriting Discounts And Commissions And Offering Costs ProceedsFromInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissionsAndOfferingCosts	119582000
CY2022	rxst	Proceeds From Issuance Of Common Stock In At The Market Offerings ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings	6050000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	121000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27000
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	587000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2022	rxst	Change In Notes Receivable For Redeemable Common Stock Issued Financing Activities ChangeInNotesReceivableForRedeemableCommonStockIssuedFinancingActivities	0
CY2021	rxst	Change In Notes Receivable For Redeemable Common Stock Issued Financing Activities ChangeInNotesReceivableForRedeemableCommonStockIssuedFinancingActivities	575000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1554000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6332000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	137342000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12577000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10717000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25172000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14455000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12595000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25172000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2187000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1269000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	20000
CY2022	rxst	Interest Paid On Financing Leases InterestPaidOnFinancingLeases	18000
CY2021	rxst	Interest Paid On Financing Leases InterestPaidOnFinancingLeases	5000
CY2022	rxst	Interest Paid On Term Loan InterestPaidOnTermLoan	4239000
CY2021	rxst	Interest Paid On Term Loan InterestPaidOnTermLoan	3182000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	126000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	311000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2022	rxst	Operating Lease Obligations Incurred OperatingLeaseObligationsIncurred	1090000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1090000
CY2021	rxst	Operating Lease Obligations Incurred OperatingLeaseObligationsIncurred	126000
CY2022	rxst	Finance Lease Obligations Incurred FinanceLeaseObligationsIncurred	311000
CY2021	rxst	Finance Lease Obligations Incurred FinanceLeaseObligationsIncurred	0
CY2021	rxst	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	0
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	0
CY2022	rxst	Reclassification Of Shares Of Redeemable Common Stock To Common Stock Assumed In Non Cash Investing Or Financing Activity ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity	0
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	299000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	28000
CY2022	rxst	Reclassification From Warrant Liability To Additional Paid In Capital For Warrants Exercised ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised	0
CY2022	rxst	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	133000
CY2021	rxst	Reclassification From Warrant Liability To Additional Paid In Capital For Warrants Exercised ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised	1111000
CY2022	rxst	Reclassification Of Redeemable Common Stock To Common Stock Options Assumed In Non Cash Investing Or Financing Activity ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity	0
CY2021	rxst	Reclassification Of Redeemable Common Stock To Common Stock Options Assumed In Non Cash Investing Or Financing Activity ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity	47370000
CY2022	rxst	Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering ConversionOfPreferredStockToCommonStockUponInitialPublicOffering	0
CY2021	rxst	Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering ConversionOfPreferredStockToCommonStockUponInitialPublicOffering	357202000
CY2022	rxst	Reclassification Of Deferred Cost ReclassificationOfDeferredCost	90000
CY2021	rxst	Reclassification Of Shares Of Redeemable Common Stock To Common Stock Assumed In Non Cash Investing Or Financing Activity ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity	87702000
CY2021	rxst	Reclassification Of Deferred Cost ReclassificationOfDeferredCost	3156000
CY2022	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	4093995
CY2022	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	4093995
CY2021	rxst	Operating Income Loss1 OperatingIncomeLoss1	52800000
CY2022	rxst	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10.33
CY2022Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	14725309
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	105800000
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	159300000
CY2022	rxst	Operating Income Loss1 OperatingIncomeLoss1	63300000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	811000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12595000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25172000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the consolidated financial<br/> statements and disclosures in the accompanying notes as of the date of the accompanying consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to predict. Actual results may differ materially from the estimates used in the preparation of the accompanying consolidated financial statements under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company’s consolidated financial statements as of and for the year ended December 31, 2022 reflect the Company’s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates, foreign exchange rate fluctuations and the COVID-19 pandemic. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.</span></p>
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	75000
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	9000
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	0
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	0
CY2022	rxst	Increased Decreased In Restricted Cash IncreasedDecreasedInRestrictedCash	50000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	761000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11834000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24361000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	761000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company’s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money market funds and U.S. treasury bills. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company’s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company’s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company’s business and may impact business in the future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2022	rxst	Accounts Receivable Percentage AccountsReceivablePercentage	0.10
CY2021	rxst	Accounts Receivable Percentage AccountsReceivablePercentage	0.10
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2022Q4	rxst	Liability On Uncertain Tax Position LiabilityOnUncertainTaxPosition	0
CY2021Q4	rxst	Liability On Uncertain Tax Position LiabilityOnUncertainTaxPosition	0
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021Q4	us-gaap	Inventory Net InventoryNet	8032000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	30036000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27562000
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	0
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	0
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6408000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4451000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6494000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2828000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2567000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	868000
CY2022Q4	us-gaap	Inventory Gross InventoryGross	15469000
CY2021Q4	us-gaap	Inventory Gross InventoryGross	8147000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	634000
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	115000
CY2022Q4	us-gaap	Inventory Net InventoryNet	14835000
CY2022Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	2800000
CY2021Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	1800000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2332000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19898000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16345000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1006000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12672000
CY2022Q4	rxst	Accrued Interest Current AccruedInterestCurrent	455000
CY2021Q4	rxst	Accrued Interest Current AccruedInterestCurrent	319000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7859000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10138000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11217000
CY2022	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	3900000
CY2021	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	4000000.0
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	102877000
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	156361000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5000000.0
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	8846000
CY2021	rxst	Exercise Of Preferred Stock Warrants ExerciseOfPreferredStockWarrants	-1111000
CY2021	rxst	Expiration Of Common Stock Warrants ExpirationOfCommonStockWarrants	-5018000
CY2021	rxst	Gain Loss From Changes In Fair Value Of Preferred Stock Warrants GainLossFromChangesInFairValueOfPreferredStockWarrants	-2717000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	8537000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5916000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1348000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	618000
CY2022	us-gaap	Long Term Debt Description LongTermDebtDescription	The Amended Term Loan requires 35 months of interest-only payments, followed by 22-months of principal and accrued interest payments. If the Company is in compliance with its performance-to-plan covenant through April 1, 2025 and has not provided an IP lien election notice before May 1, 2025, the interest-only period is extended by 12 months, and the amortization period is reduced to ten months. Payments are due on the first day of each month in arrears. All unpaid amounts under the Amended Term Loan mature on February 1, 2027.
CY2022	us-gaap	Short Term Debt Description ShortTermDebtDescription	Under the Amended Term Loan, a final payment (“Final Payment”) will be due at the earlier of the maturity date, acceleration of the loans, or a voluntary or mandatory prepayment of the loans, in an amount equal to (a) if the Final Payment is paid on or after January 1, 2022 through and including October 31, 2022, three percent (3.00%) of the original principal amount of the loans (or, in the case of a partial prepayment, the amount of principal to be prepaid), (b) if the Final Payment is paid on or after November 1, 2022 through and including October 31, 2023, four percent (4.00%) of the original principal amount of the loans (or, in the case of a partial prepayment, the amount of principal to be prepaid) and (c) if the Final Payment is paid on or after November 1, 2023, five percent (5.00%) of the original principal amount of the loans (or, in the case of a partial prepayment, the amount of principal to be prepaid). The Final Payment is being accreted to the carrying value of the debt as a debt premium and interest expense over the life of the loan using the effective interest method.
	rxst	Interest Rate On Borrowings Term Loan InterestRateOnBorrowingsTermLoan	0.0300
CY2023	rxst	Interest Rate On Borrowings Term Loan InterestRateOnBorrowingsTermLoan	0.0400
CY2023Q4	rxst	Interest Rate On Borrowings Term Loan InterestRateOnBorrowingsTermLoan	0.0500
CY2022Q4	us-gaap	Financing Receivable Unamortized Loan Fee Cost FinancingReceivableUnamortizedLoanFeeCost	100000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	0
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	0
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	16364000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	21818000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive	1818000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	169000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	40169000
CY2022	rxst	Schedule Of Cash Interest Paid And Effective Interest Rate On Term Loan Table Textblock ScheduleOfCashInterestPaidAndEffectiveInterestRateOnTermLoanTableTextblock	<p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">For the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022 and 2021 the cash interest paid and effective interest rate on the Amended Term Loan and Term Loan were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.871%;"/> <td style="width:2.318%;"/> <td style="width:1.0%;"/> <td style="width:19.467000000000002%;"/> <td style="width:1.0%;"/> <td style="width:1.0%;"/> <td style="width:19.344%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">For the Year Ended December 31,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Cash interest paid</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.66</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9.25</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Effective interest rate</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">12.19</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.90</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">%</span></p></td> </tr> </table>
CY2022	rxst	Cash Interest Paid Percentage Period CashInterestPaidPercentagePeriod	0.1066
CY2021	rxst	Cash Interest Paid Percentage Period CashInterestPaidPercentagePeriod	0.0925
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.1219
CY2021	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.1090
CY2022	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife	P6Y1M6D
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6100000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8800000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.624
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.649
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.631
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.616
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.637
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.632
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.020
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.038
CY2022	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate	0.027
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.006
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.017
CY2021	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate	0.010
CY2021	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife	P6Y1M6D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield	0.000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield	0.000
CY2022	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue	12.73
CY2021	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue	15.02
CY2022Q3	rxst	Securities Issuable Value Under Self Registration Statement Form SecuritiesIssuableValueUnderSelfRegistrationStatementForm	200000000.0
CY2022Q3	us-gaap	Registration Payment Arrangement Term RegistrationPaymentArrangementTerm	three years
CY2022Q3	us-gaap	Registration Payment Arrangement Gains And Losses RegistrationPaymentArrangementGainsAndLosses	200000000.0
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	475875
CY2022Q4	rxst	Common Stock Sale Underwriting Discounts And Commission Deducted CommonStockSaleUnderwritingDiscountsAndCommissionDeducted	6000000.0
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10951460
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6878511
CY2022Q4	rxst	Closing Stock Price ClosingStockPrice	12.67
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-66750000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-48694000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	14000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-66747000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48680000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-11366000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-9950000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3542000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3241000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-14908000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-13191000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14908000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13191000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	70179000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	62347000
CY2022Q4	rxst	Deferred Tax Asset Amortization DeferredTaxAssetAmortization	99000
CY2021Q4	rxst	Deferred Tax Asset Amortization DeferredTaxAssetAmortization	117000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4879000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2960000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2829000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9202000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7902000
CY2022Q4	rxst	Deferred Tax Asset Right Of Use Of Liability DeferredTaxAssetRightOfUseOfLiability	1204000
CY2021Q4	rxst	Deferred Tax Asset Right Of Use Of Liability DeferredTaxAssetRightOfUseOfLiability	1290000
CY2022Q4	rxst	Deferred Tax Asset Depreciation DeferredTaxAssetDepreciation	779000
CY2021Q4	rxst	Deferred Tax Asset Depreciation DeferredTaxAssetDepreciation	536000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2332000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1745000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	91634000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	76766000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	90471000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	75546000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1163000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1220000
CY2022Q4	rxst	Deferred Tax Asset Right Of Use Of Asset DeferredTaxAssetRightOfUseOfAsset	1163000
CY2021Q4	rxst	Deferred Tax Asset Right Of Use Of Asset DeferredTaxAssetRightOfUseOfAsset	1220000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1163000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1220000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	128800000
CY2022Q4	rxst	State Operating Loss Carry Forwards Not Expire StateOperatingLossCarryForwardsNotExpire	17600000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	14017000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	10223000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.035
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2358000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1989000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.019
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-1269000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.026
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-1241000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.024
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1625000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.014
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-677000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.002
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-105000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.026
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	1252000
CY2022	rxst	Effective Income Tax Rate Reconciliation Limitation And Credit Carry Forwards Subject To Expiration EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration	-0.015
CY2022	rxst	Income Tax Reconciliation Limitation And Credit Carry Forwards Subject To Expiration IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration	-988000
CY2021	rxst	Effective Income Tax Rate Reconciliation Limitation And Credit Carry Forwards Subject To Expiration EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration	-0.020
CY2021	rxst	Income Tax Reconciliation Limitation And Credit Carry Forwards Subject To Expiration IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration	-960000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.000
CY2022	rxst	Income Tax Reconciliation Tax Credit Other IncomeTaxReconciliationTaxCreditOther	27000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.002
CY2021	rxst	Income Tax Reconciliation Tax Credit Other IncomeTaxReconciliationTaxCreditOther	-113000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.223
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-14908000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.271
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-13189000
CY2022	rxst	Effective Income Tax Reconciliation Tax Credits EffectiveIncomeTaxReconciliationTaxCredits	0.000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	9000
CY2021	rxst	Effective Income Tax Reconciliation Tax Credits EffectiveIncomeTaxReconciliationTaxCredits	0.000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	8000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14900000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13200000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	300400000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	128800000
CY2022Q4	rxst	Taxable Income Offset Percentage TaxableIncomeOffsetPercentage	0.80
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	300400000
CY2022Q4	rxst	Federal Operating Loss Carry Forwards Not Expire FederalOperatingLossCarryForwardsNotExpire	188900000
CY2022Q4	rxst	Taxable Income Offset Percentage TaxableIncomeOffsetPercentage	0.80
CY2022Q4	rxst	Taxable Income Offset Percentage TaxableIncomeOffsetPercentage	0.80
CY2022Q4	rxst	Federal Operating Loss Carry Forwards FederalOperatingLossCarryForwards	8200000
CY2022Q4	rxst	State Operating Loss Carry Forwards StateOperatingLossCarryForwards	8000000.0
CY2022Q3	rxst	Investment Credit Percentage InvestmentCreditPercentage	0.25
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company’s net operating loss and R&D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3013000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2554000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	481000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	459000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3494000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3013000
CY2022	us-gaap	Foreign Earnings Repatriated ForeignEarningsRepatriated	0
CY2021	us-gaap	Foreign Earnings Repatriated ForeignEarningsRepatriated	0
CY2022Q2	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P34M
CY2022Q2	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2025-03-31
CY2022Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	11410
CY2023Q1	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	5319
CY2023Q1	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2023-03-01
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3943000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4284000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	206000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	33000
CY2022Q4	rxst	Total Lease Assets TotalLeaseAssets	4149000
CY2021Q4	rxst	Total Lease Assets TotalLeaseAssets	4317000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1818000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1509000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	152000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	20000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2813000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3625000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	43000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	17000
CY2022Q4	rxst	Total Lease Liabilities TotalLeaseLiabilities	4826000
CY2021Q4	rxst	Total Lease Liabilities TotalLeaseLiabilities	5171000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	18000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2128000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	164000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1876000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	40000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1024000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	6000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	79000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5107000
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	210000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	476000
CY2022Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	15000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4631000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	195000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M1D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M14D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M19D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.103
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.095
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.105
CY2022	us-gaap	Legal Fees LegalFees	0
CY2021	us-gaap	Legal Fees LegalFees	0
CY2021Q3	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.02
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.25
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	688000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	228000

Files In Submission

Name	View Source	Status
rxst-20221231_def.xml	Edgar Link	unprocessable
rxst-20221231_pre.xml	Edgar Link	unprocessable
0000950170-23-006237-index-headers.html	Edgar Link	pending
0000950170-23-006237-index.html	Edgar Link	pending
0000950170-23-006237.txt	Edgar Link	pending
0000950170-23-006237-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img49891875_0.jpg	Edgar Link	pending
img49891875_1.jpg	Edgar Link	pending
img49891875_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rxst-20221231.htm	Edgar Link	pending
rxst-20221231.xsd	Edgar Link	pending
rxst-ex10_18.htm	Edgar Link	pending
rxst-ex10_35.htm	Edgar Link	pending
rxst-ex23_1.htm	Edgar Link	pending
rxst-20221231_htm.xml	Edgar Link	completed
rxst-ex31_1.htm	Edgar Link	pending
rxst-ex31_2.htm	Edgar Link	pending
rxst-ex32_1.htm	Edgar Link	pending
rxst-ex32_2.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rxst-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
rxst-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RXST
Rxsight Inc Stock $rxst

2023 Q1 Form 10-K Financial Statement

#000095017023006237 Filed on March 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RXST Rxsight Inc Stock $rxst

2023 Q1 Form 10-K Financial Statement

#000095017023006237 Filed on March 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RXST
Rxsight Inc Stock $rxst